AbbVie’s mega-blockbuster Humira is facing biosimilar competition, but another patent licensing agreement, this time with Mylan, sees the company securing exclusivity through to 2023 in the US. https://www.biopharma-reporter.com/Article/2018/07/17/Mylan-becomes-latest-to-strike-licensing-deal-with-AbbVie-for-Humira-biosimilar
Haythem Y. Ali, MD, discusses the state of biosimilar development and implementation in the field of oncology. https://www.onclive.com/web-exclusives/expert-predicts-the-trajectory-of-biosimilars-in-oncology
The European Commission has given its approval to Sandoz, Novartis’ generics and biosimilars unit, for its biosimilar version of Janssen’s Remicade (infliximab) and other products, known as Zessly.
The therapy has been authorised in all the indications of its reference product, which includes the treatment of rheumatoid arthritis, adult Crohn’s disease, paediatric Crohn’s disease, adult ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
read more http://www.pharmafile.com/news/517453/novartis-sandoz-scores-eu-approval-remicade-biosimilar
(Reuters) – AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023.
The European conglomerate will commercialize the South Korean company’s copycat version of Herceptin. https://www.biopharmadive.com/news/mundipharma-inks-third-biosimilar-deal-with-celltrion/519580/
The trade body for generics and biosimilar manufacturers warns of barriers to entry for its products. https://www.biopharmadive.com/news/industry-touts-savings-potential-of-generics-and-biosimilars/517098/
Biogen has reported record biosimilar revenues and says it intends to increase its share in Samsung Bioepis. https://www.biopharma-reporter.com/Article/2018/01/26/Biogen-looking-to-up-its-stake-in-Samsung-biosimilar-JV
Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. http://www.worldpharmanews.com/novartis/4264-sandoz-announces-exclusive-global-collaboration-with-biocon-on-next-generation-biosimilars
Formycon and its commercialisation partner bioeq have positioned themselves for the potential launch of a Lucentis (ranibizumab) biosimilar in 2020. https://www.biopharma-reporter.com/Article/2017/11/28/Lucentis-biosimilar-Formycon-eyes-2020-for-US-launch
Humira is the key drug for AbbVie, and one the company hopes it will be able to push into the $20 billion region per year region before competition arrives. After a financial deal was agreed with Amgen, it looks like the drug should have the immediate biosimilar threat removed from its path running up to the beginning of 2023.
read more http://www.pharmafile.com/news/515253/five-more-biosimilar-free-years-abbvie-s-humira